Telix Pharma Mediaroom - PR Newswire APAC

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2025-12-08 06:08 563

Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held

MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-11-21 14:22 3010

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-11-20 03:00 1113

OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer

MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-11-12 04:00 1201

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-10-23 19:00 1029

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-10-23 04:00 1303

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-10-14 14:59 1344

Telix Announces Record-Breaking Presence at EANM 2025

MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDA...

2025-10-01 13:57 1706

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2025-09-10 07:01 1372

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-08-21 08:23 2574

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-07-30 07:00 2865

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-07-22 16:02 2531

Gozellix Receives Permanent HCPCS Code

MELBOURNE, Australia, July 9, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:...

2025-07-09 12:41 3203

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2025-06-04 06:30 3662

Telix at ANZSNM Annual Scientific Meeting 2025

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:...

2025-05-20 06:00 2442

Illuccix China Phase 3 Study Completes Enrolment

MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2025-05-13 07:22 1921

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (A...

2025-05-08 05:00 2223

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent ...

2025-04-29 06:30 2160

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2025-04-16 06:45 2358

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2025-04-07 07:09 3830

Latest News